Unveiling 4 Analyst Insights On PROCEPT BioRobotics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2024
0mins
Should l Buy ?
Source: NASDAQ.COM
Analyst Ratings Overview: Recent ratings for PROCEPT BioRobotics show a mix of bullish and bearish sentiments from four analysts, with an average 12-month price target of $79.0, reflecting a 6.04% increase from previous estimates.
Financial Performance Insights: The company has achieved significant revenue growth of 61.17% over three months, but faces challenges with profitability as indicated by a net margin of -48.03%, along with below-average return metrics on equity and assets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
